Collaborations Pharmaceuticals

Rare Disease Treatments

Collaboration Pharmaceuticals is developing therapeutics for multiple rare and infectious diseases. AI is revolutionizing the process of drug discovery. Collaboration Pharmaceuticals is developing and applying their AI software to identify and translate molecules to early preclinical to clinical stage assets. This includes MegaTox®, MegaTrans® and MegaPredict®, three of their machine learning models that can be used to predict molecular properties and bioactivities. These tools have been applied to client’s projects saving costs and increasing operational efficiency. Collaboration Pharmaceuticals has used their expertise to build a pipeline of drugs against bacteria, viruses and parasites to treat rare and neglected diseases.